ResApp Health Limited (ASX: RAP) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


ResApp Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • ResApp Health Limited (ASX: RAP)
    Latest News

    A group of people in a corporate setting do a collective high five.
    Healthcare Shares

    Why is the ResApp share price lifting today?

    Progress on a takeover bid for the company has been announced.

    Read more »

    A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
    Mergers & Acquisitions

    ResApp share price explodes 50% on new Pfizer deal

    The ResApp share price is launching upwards after Pfizer upped its takeover bid for the company.

    Read more »

    A man looks down with fright as he falls towards the ground.
    Share Fallers

    Why Bowen Coking Coal, Lake Resources, Premier, and ResApp shares are tumbling lower

    These ASX shares are having a tough day...

    Read more »

    A man wearing a white coat and glasses is wide-mouthed in surprise.
    Mergers & Acquisitions

    Why is the ResApp share price crashing 29% today?

    ResApp shares have been hammered on Tuesday...

    Read more »

    a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.
    Healthcare Shares

    ResApp share price frozen as $180m Pfizer takeover bid hangs in the balance

    The value of Pfizer's takeover bid may soon come to light.

    Read more »

    four excited doctors with their hands in the air
    Share Market News

    This ASX share is defying the odds to crack new 52-week highs

    This health share is certainly kicking goals today.

    Read more »

    Stock market chart in green with a rising arrow symbolising a rising share price.
    Share Gainers

    Why Computershare, Lithium Plus, Lynas, and ResApp shares are pushing higher

    These ASX shares are pushing higher today...

    Read more »

    A young man wearing glasses and a denim shirt sits at his desk and raises his fists and screams with delight.
    Mergers & Acquisitions

    Here's why the ResApp share price is rocketing 50% today

    ResApp shares are breaking out today following an improved acquisition offer from Pfizer Australia.

    Read more »

    Green arrow going up on stock market chart, symbolising a rising share price.
    Share Gainers

    Why Australian Clinical Labs, Lake Resources, PolyNovo, and ResApp are rising

    These ASX shares are pushing higher despite the market selloff...

    Read more »

    Female doctor with a mask holds out hand in a stop gesture.
    Mergers & Acquisitions

    ResApp share price halted ahead of Pfizer takeover update

    ResApp shares have been placed on ice pending a company update.

    Read more »

    Rising green bar graph with an arrow and a world map, symbolising a rising share price.
    Share Gainers

    Why IGO, Lake Resources, Regis Resources, and ResApp shares are charging higher

    These ASX shares are charging higher on Monday...

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    ResApp share price rockets 28% on Pfizer takeover news

    ResApp has received a takeover offer from an industry giant...

    Read more »

    RAP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
    Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
    Dr Michael Stein Non-Executive Director Apr 2020
    Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
    Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
    Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
    Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
    Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
    Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
    Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
    Ms Nicola (Nicki) Maxine Farley Company Secretary
    Nicola (Nicki) Maxine Farley Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 90,509,172 10.53%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> 46,498,352 5.41%
    J P Morgan Nominees Australia Pty Limited 22,398,291 2.61%
    Mr Frank Weng Thong Chew 18,453,000 2.15%
    HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> 17,974,966 2.09%
    BNP Paribas Noms Pty Ltd <DRP> 14,977,050 1.74%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 12,567,531 1.46%
    Mr Yongsheng Peng & Mrs Yuezhen Xie 11,667,602 1.36%
    Mr Anthony James Keating 10,225,000 1.19%
    Citicorp Nominees Pty Limited 9,962,873 1.16%
    Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> 8,437,500 0.98%
    Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
    CEM International (Asia) Pty Ltd 7,849,888 0.91%
    Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> 7,510,228 0.87%
    Mr Trent Antony Goodrick 7,000,000 0.81%
    Queensland Forest Industries Pty Ltd 6,502,500 0.76%
    Mishtalem Pty Ltd 6,500,000 0.76%
    Super Dino Pty Ltd <Dino Super A/C> 5,430,779 0.63%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,378,484 0.63%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.61%